EUVIMEDScopri EUVIMED
Crossref

Bleeding Risk During Prolonged Dual Anticoagulation With Warfarin and Low‐Molecular‐Weight Heparin: A Retrospective Single‐Centre Study

Shing Fung Oscar Miao iD, Wen Kwang Lim iD, Seok Lim iD

ANZ Journal of Surgery · 2026-10 · 96 (10) · 2940-2948

DOI: 10.1111/ans.70898 ↗

At a glance

Journal article in ANZ Journal of Surgery, published online on 2026-08-02. Written by Shing Fung Oscar Miao and 2 co-authors. Institution: Division of Home First, Ambulatory and Complex Care, Royal Melbourne Hospital, Melbourne, Victoria, Australia. Major MEDLINE topics: Warfarin, Heparin, Low-Molecular-Weight, Anticoagulants, Hemorrhage. 17 references.

AbstractSubjectsDati bibliograficiCiteRelated studies

Abstract (original language)

Backgrounds Warfarin remains the anticoagulant of choice for selected high‐risk patients [1]. Its narrow therapeutic index and pharmacokinetics make perioperative management challenging. Bridging with low‐molecular‐weight heparin (LMWH) during warfarin re‐initiation reduces thromboembolic risk but may increase bleeding risk.

Methods

We conducted a retrospective cohort study on patients managed through the Hospital‐in‐the‐Home (HITH) service at a tertiary centre in Melbourne, Australia. All patients admitted between 1 January and 31 December 2024 undergoing warfarin re‐initiation with therapeutic‐dose LMWH bridging were included. The primary outcome was bleeding incidence and severity during dual anticoagulation, defined by International Society of Thrombosis and Haemostasis (ISTH) criteria. Secondary analyses evaluated clinical and surgical factors associated with bleeding.

Results

Of 2348 HITH admissions, 129 patients were included. Bleeding occurred in 21 patients (16%), including 3 major and 18 minor events; there were no thromboembolic events or deaths. Most bleeding was managed in the community with only two requiring procedural intervention. Postoperative patients had higher bleeding incidence than non‐operative re‐initiators (23.9% vs. 8.1%; RR 2.96, 95% CI 1.15–7.60; OR 3.58, 95% CI 1.22–10.46; Fisher's exact p = 0.0175). Bleeding occurred at a median of 6 days of dual therapy. Previous long‐term warfarin use, renal impairment, higher target INR and elevated anti‐Xa exposure were associated with bleeding; target INR and anti‐Xa remained independently associated with bleeding on multivariable analysis.

Conclusions

Bleeding risk was more strongly associated with patient‐ and treatment‐related risk factors than bridging duration alone. These findings support risk‐stratified warfarin re‐initiation and early monitoring during dual therapy.

Subjects

MeSH terms (MEDLINE)

WarfarinHeparin, Low-Molecular-WeightAnticoagulantsHemorrhageThromboembolismHumansRetrospective StudiesFemaleMaleAgedAnticoagulation BridgeIncidenceRisk FactorsMiddle AgedAged, 80 and over

Author keywords

haemorrhageheparinhome care serviceshospital‐basedlow‐molecular‐weightperioperative carewarfarin

Substances

WarfarinHeparin, Low-Molecular-WeightAnticoagulants

Authors and institutions

  • Division of Home First, Ambulatory and Complex Care, Royal Melbourne Hospital, Melbourne, Victoria, Australia.
  • Department of Medicine, Faculty of Medicine, Dentistry and Health Sciences, The University of Melbourne, Melbourne, Victoria, Australia.

ORCID profiles: Shing Fung Oscar Miao, Wen Kwang Lim, Seok Lim

Cite

APA

Miao, S. F. O., Lim, W. K., & Lim, S. (2026). Bleeding Risk During Prolonged Dual Anticoagulation With Warfarin and Low‐Molecular‐Weight Heparin: A Retrospective Single‐Centre Study. ANZ Journal of Surgery, 96(10), 2940-2948. https://doi.org/10.1111/ans.70898

Vancouver

Miao SFO, Lim WK, Lim S. Bleeding Risk During Prolonged Dual Anticoagulation With Warfarin and Low‐Molecular‐Weight Heparin: A Retrospective Single‐Centre Study. ANZ Journal of Surgery. 2026;96(10):2940-2948. doi:10.1111/ans.70898

BibTeX
@article{Miao2026,
  author = {Miao, Shing Fung Oscar and Lim, Wen Kwang and Lim, Seok},
  title = {Bleeding Risk During Prolonged Dual Anticoagulation With Warfarin and Low‐Molecular‐Weight Heparin: A Retrospective Single‐Centre Study},
  journal = {ANZ Journal of Surgery},
  year = {2026},
  volume = {96},
  number = {10},
  pages = {2940--2948},
  doi = {10.1111/ans.70898}
}
Start for free →